 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Benitec Biopharma Inc. (NASDAQ:BNTC  Get Free Report) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 5,100 shares, a...

Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Down 68.3% in March

Benitec Biopharma (NASDAQ:BNTC  Free Report) had its price objective hoisted by JMP Securities from $8.00 to $10.00 in a research report report published on Thursday morning, Benzinga reports...

Benitec Biopharma (NASDAQ:BNTC) Price Target Increased to $10.00 by Analysts at JMP Securities

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Benitec Biopharma price target raised by $2 at JMP Securities, here's why

-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit...

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

Benitec Biopharma Inc. (NASDAQ:BNTC  Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 6,200 shares...

Benitec Biopharma Inc. (NASDAQ:BNTC) Sees Significant Drop in Short Interest

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.

Volume (M)	3.52M
52-Wk High	$9.01
52-Wk Low	$1.86

BNTC Benitec Biopharma Inc

About

Feed

News

Sentiment

Fundamentals